

## Special Issue

# Activation and Regulation of NLRP3 Inflammasome

### Message from the Guest Editor

The NLRP3 inflammasome represents one of the most extensively studied innate immune complexes and plays a crucial role in the host defense against pathogens and cellular damage. However, dysregulation of NLRP3 inflammasome activation contributes to the pathogenesis of numerous inflammatory, metabolic, and neurodegenerative disorders. This Special Issue aims to compile cutting-edge research and comprehensive reviews focusing on the molecular mechanisms governing NLRP3 inflammasome activation, regulation, and its implications in health and disease. We welcome original research articles and reviews that explore various aspects of NLRP3 inflammasome biology, including but not limited to structural insights into assembly and activation; novel regulatory mechanisms involving post-translational modifications; crosstalk with other cellular pathways such as autophagy, mitochondrial dynamics, and metabolic processes; roles in specific disease contexts; and innovative therapeutic strategies targeting the NLRP3 inflammasome. Emerging technologies for studying inflammasome dynamics and the development of selective NLRP3 inhibitors are also of particular interest.

---

### Guest Editor

Dr. Wei Guo

Department of Pharmacology, School of Pharmacy, Fudan University, Shanghai 201301, China

---

### Deadline for manuscript submissions

closed (30 November 2025)



## Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.5  
CiteScore 7.8  
Indexed in PubMed



[mdpi.com/si/240294](https://mdpi.com/si/240294)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.5  
CiteScore 7.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.2 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2026).